Lenaic Nathanael Teyssedou

CIK: 0002123881

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)8 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ADXN

Addex Therapeutics Ltd.

Officer

Discretionary Trading P&L

Holdings

Transaction History (16 total)

ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
37.8K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
37.8K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
59.5K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
59.5K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
10K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
10K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
30K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
30K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
65.6K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
65.6K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
90.5K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
90.5K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
209K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
209K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Disposition(D)
Stock-option (Right to Buy)
Direct
100.5K shares-
ADXN
Addex Therapeutics Ltd.
Sep 2, 2026
Award(A)
Stock-option (Right to Buy)
Direct
100.5K shares-

		Type	Shares	Price		Ownership
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	37,770	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	37,770	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	59,530	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	59,530	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	10,000	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	10,000	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	30,000	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	30,000	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	65,620	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	65,620	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	90,529	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	90,529	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	208,974	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	208,974	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Disposition(D) Stock-option (Right to Buy)	100,485	-	-	Direct
Sep 2, 2026	ADXN Addex Therapeutics Ltd.	Award(A) Stock-option (Right to Buy)	100,485	-	-	Direct

1-16 of 16 transactions

About Teyssedou Lenaic Nathanael

Teyssedou Lenaic Nathanael (SEC CIK 0002123881) files insider reports with the SEC as PRINCIPAL ACCOUNTING OFFICER of Addex Therapeutics Ltd. (ADXN).

Signal8 holds 2 ownership filings by Teyssedou Lenaic Nathanael (1 Form 3, 1 Form 4), filed between Mar 25, 2026 and Sep 4, 2026. Those filings report 16 transactions, the latest on Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Teyssedou Lenaic Nathanael's filings is in GENEVA.

Recent filings by Teyssedou Lenaic Nathanael

Sep 2, 2026: Disposition to issuer transaction of ADXN derivative securities (Form 4, code D).
Sep 2, 2026: Grant or award of ADXN derivative securities (Form 4, code A).
Sep 2, 2026: Disposition to issuer transaction of ADXN derivative securities (Form 4, code D).
Sep 2, 2026: Grant or award of ADXN derivative securities (Form 4, code A).
Sep 2, 2026: Disposition to issuer transaction of ADXN derivative securities (Form 4, code D).

Other insiders filing for Addex Therapeutics Ltd. (ADXN)

Kalinichev Mikhail, HEAD OF TRANSLATIONAL SCIENCE
Nunn Jason Raleigh, Director
Mills Roger, CHIEF MEDICAL OFFICER
Manke Isaac, Director
Lawton Vincent Michael, Director
Hill Raymond George, Director

How to read Form 4 transaction codes